Corcept Therapeutics (CORT) Announces Positive Prelim. Data from Mifepristone Phase 1/2 in TNBC; Efficacy Results Indicate Combo Active
Tweet Send to a Friend
Corcept Therapeutics Incorporated:Preliminary efficacy results in Phase 1/2 trial of mifepristone plus eribulin (Eisai's Halaven®) to treat triple-negative breast cancer ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
